(ATD) Asterand
Summary
|
|
|||||||||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||||||||
| Headline | Source | |||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
||||||||||||||||||||||||||||||||
| 30-01-12 | RNS |
|||||||||||||||||||||||||||||||
|
RNS Number : 3782W Asterand PLC 30 January 2012
Asterand Subsidiary BioSeek and US EPA Expand ToxCast™ Collaboration
BioSeek's BioMAP® Systems Platform Used to Predict Toxicity of Environmental and Other Compounds on Human Health
Detroit, MI (January 30 2012):Asterand plc (LSE: ATD) today announced that the U.S. Environmental Protection Agency (EPA) has expanded its collaboration and Phase II funding commitment with Asterand's subsidiary BioSeek LLC. Under the EPA ToxCast™ screening program, BioSeek is employing its unique BioMAP® Systems human primary cell assay platform to predict the biological activity and potential toxicity of environmental and other chemicals on human health. The new agreement provides $696,000 in additional funding for BioSeek and adds a further 100 compounds to the more than 1000 environmental compounds, pesticides, failed pharmaceuticals, and nanomaterials already analyzed using BioMAP Systems in this ongoing effort.
"Through our work with EPA, BioMAP is yielding a rich harvest of biological information on a wide variety of environmental and other chemicals and their potential effects on human health," said Ellen Berg, Ph.D., General Manager of BioSeek. "The long-term goal of the ToxCastTM program is to establish in vitro assays that can forecast the toxicity of chemical compounds and other materials in humans and animals, and several of our primary human cell assays are contributing to predictive models in this effort."
"As later phases of the ToxCast program include a variety of pharmaceutical compounds," Dr. Berg continued, "our proprietary BioMAP compound database is gaining a rich dataset for mining with our pharmaceutical partners, to help understand the activities and potential safety of their own compounds in the context of human biology. Such insights can then be applied to better prioritize compounds in development prior to undertaking costly human clinical trials."
"We commend EPA's efforts to develop superior techniques for predicting the potential health risks of environmental chemicals through its ToxCast program," said Jack Davis, Chairman and Interim Chief Executive Officer of Asterand plc. "We look forward to continuing our support of the EPA in this endeavour."
About BioMAP
BioSeek's proprietary BioMAP technology platform bridges the gap between in vitro and in vivo testing and connects primary human cell-based assay data to clinically relevant results. Compounds tested in BioMAP Assay Systems generate biological activity profiles that are compared to those of thousands of well-characterized agents in our proprietary BioMAP database, using a variety of predictive computational analyses. BioMAP Assay Systems are physiologically relevant and concurrently provide multifactorial readouts relevant to compound efficacy and safety. Thus, a compound's detected activities effectively preview in vivo results and forecast potential clinical outcomes. The BioMAP technology platform is consistently reproducible within and between assays, is high throughput, and supports drug discovery programs from library screening to lead optimization and candidate selection. For more information on BioMAP, please visit our website at http://www.bioseekinc.com/.
About Asterand
Asterand plc is a leading supplier of high quality human tissue and tissue-based services. Our comprehensive approach to human tissue and research services offers pharmaceutical, biotech and diagnostic companies the unique opportunity to have one company meet all of their human biomaterial needs along the continuum of drug discovery and development. BioSeek LLC, a wholly-owned subsidiary of Asterand plc, is improving the success rate of pharmaceutical research and development by integrating human biology from the earliest stages of drug discovery onward through its unique BioMAP® predictive human-based models. Our mission is to accelerate target discovery and drug compound validation and enable our clients to take safer and more effective drugs into the market.
For more information about Asterand and BioSeek, please visit http://www.asterand.com
About the US EPA ToxCastTM Program
- END -
Contacts:
BioSeek LLC Ivan Plavec, VP Business Development Tel: +1 (650) 416 7629
Asterand plc Jack Davis, Chairman and Interim Chief Executive Officer Tel: + 44 (0) 1763 211 600 / + 1 (313) 263-0960 Buchanan Communications Lisa Baderoon / Mark Court / Isabel Podda Tel: +44 (0) 20 7466 5000
Daniel Stewart & Company plc Antony Legge Tel: +44 (0) 20 7776 6550 This information is provided by RNS The company news service from the London Stock Exchange More |
||||||||||||||||||||||||||||||||
| 05-01-12 | RNS |
|||||||||||||||||||||||||||||||
|
RNS Number : 0086V Asterand PLC 05 January 2012 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF THAT JURISDICTION. This announcement is not an announcement of a firm intention to make an offer under Rule 2.7 of the City Code on Takeovers and Mergers (the "Takeover Code") and there can be no certainty that an offer will be made, nor as to the terms on which any offer will be made. 5 January 2012 Asterand Plc ("Asterand" or the "Company") Update on Formal Sale Process
On 17 November 2011, the Company announced its expected timeframe for the submission of potential offers for Asterand. Since then, the Company and its advisors, Covington Associates LLC ("Covington") and Daniel Stewart & Company plc ("Daniel Stewart"), have received strong interest from a number of parties. However, it was not possible to complete the various conversations prior to the Christmas break and the Company has decided to extend the timetable by approximately two weeks so that the potential offerors now have until 17 January 2012 to submit their proposed offers, with the intention of being able to announce a recommended offer by the middle of February. The Company continues to update its key creditors on the process and the developments to date. Shareholders should note that whilst the Board is working to secure a recommended offer by the middle of February 2012, there is no guarantee that an offer will be made, or even proposed, or as to the level of any proposal or offer that may be made. If a recommended offer is secured by the targeted date, the Board anticipates that an offer document would then be posted in the subsequent 28 days. The Board reserves the right to alter any aspect of the sale process as outlined above or to terminate it at any time and in such cases will make an announcement as appropriate. The Board reserves the right to reject any approach or terminate discussions with any interested party or participant at any time. For further information, please contact:
A copy of this announcement will be available at www.asterand.co.uk. The content of the website referred to in this announcement is not incorporated into and does not form part of this announcement. Daniel Stewart (which is authorised and regulated in the United Kingdom by the Financial Services Authority) is acting exclusively for the Company and for no one else in connection with any possible offer and will not be responsible to anyone other than the Company for providing the protections afforded to Daniel Stewart's clients nor for providing advice in relation to any possible offer or any other matters referred to in this announcement. This announcement is not intended to, and does not, constitute or form part of any offer, invitation or the solicitation of an offer to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of, any securities whether pursuant to this announcement or otherwise. The distribution of this announcement in jurisdictions outside the United Kingdom may be restricted by law and therefore persons into whose possession this announcement comes should inform themselves about, and observe, such restrictions. Any failure to comply with the restrictions may constitute a violation of the securities law of any such jurisdiction. Disclosure requirements of the Code Under Rule 8.3(a) of the Code, any person who is interested in 1% or more of any class of relevant securities of an offeree company or of any paper offeror (being any offeror other than an offeror in respect of which it has been announced that its offer is, or is likely to be, solely in cash) must make an Opening Position Disclosure following the commencement of the offer period and, if later, following the announcement in which any paper offeror is first identified. An Opening Position Disclosure must contain details of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any paper offeror(s). An Opening Position Disclosure by a person to whom Rule 8.3(a) applies must be made by no later than 3.30 pm (London time) on the 10th business day following the commencement of the offer period and, if appropriate, by no later than 3.30 pm (London time) on the 10th business day following the announcement in which any paper offeror is first identified. Relevant persons who deal in the relevant securities of the offeree company or of a paper offeror prior to the deadline for making an Opening Position Disclosure must instead make a Dealing Disclosure. Under Rule 8.3(b) of the Code, any person who is, or becomes, interested in 1% or more of any class of relevant securities of the offeree company or of any paper offeror must make a Dealing Disclosure if the person deals in any relevant securities of the offeree company or of any paper offeror. A Dealing Disclosure must contain details of the dealing concerned and of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any paper offeror, save to the extent that these details have previously been disclosed under Rule 8. A Dealing Disclosure by a person to whom Rule 8.3(b) applies must be made by no later than 3.30 pm (London time) on the business day following the date of the relevant dealing. If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire or control an interest in relevant securities of an offeree company or a paper offeror, they will be deemed to be a single person for the purpose of Rule 8.3. Opening Position Disclosures must also be made by the offeree company and by any offeror and Dealing Disclosures must also be made by the offeree company, by any offeror and by any persons acting in concert with any of them (see Rules 8.1, 8.2 and 8.4). Details of the offeree and offeror companies in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure Table on the Takeover Panel's website at www.thetakeoverpanel.org.uk, including details of the number of relevant securities in issue, when the offer period commenced and when any offeror was first identified. If you are in any doubt as to whether you are required to make an Opening Position Disclosure or a Dealing Disclosure, you should contact the Panel's Market Surveillance Unit on +44 (0)20 7638 0129. This information is provided by RNS The company news service from the London Stock Exchange More |
||||||||||||||||||||||||||||||||
| 30-11-11 | RNS |
|||||||||||||||||||||||||||||||
|
RNS Number : 0030T Asterand PLC 30 November 2011
For Immediate Release
Asterand's Subsidiary BioSeek Achieves A Research Milestone In Drug Discovery Collaboration With Ono
SOUTH SAN FRANCISCO, CA, USA- November 30, 2011- BioSeek, LLC, a subsidiary of Asterand plc (LSE: ATD), a pioneer in the application of predictive human biology to drug discovery, announced today that the first research milestonehas been achieved in the multi-year drug discovery collaboration with Ono Pharmaceutical Co., Ltd., ("Ono"), where BioSeek is applying its proprietary BioMAP® platform to perform phenotypic screening, hit identification, lead optimization and clinical candidate selection on a target selected by Ono. Under the three-year agreement, BioSeek is receiving research funding and is eligible to receive success payments based on the research-phase progress of this collaboration and further milestone payments based on the clinical development-phase progress of a drug candidate discovered under this collaboration. Ono will have worldwide rights to develop and sell all pharmaceutical products discovered through the collaboration..
Jack Davis, Chairman and Interim Chief Executive Officer of Asterand commented: "We highly value our relationship with Ono since it enables us to take full advantage of BioMAP®'s power to discover and develop innovative new drug candidates. We are looking forward to the successful continuation and further achievements of the collaboration." BioMAP® Systems are primary cell-based models of human disease biology, designed to replicate the intricate cell and pathway interactions as they are observed in human pharmacology and toxicology. Depending on their mechanism of action, compounds induce specific patterns of changes in these systems (BioMAP® profiles) that can be compared to a large number of reference profiles in the BioMAP® Database. Assessment with BioMAP® provides early insight into human pharmacological and toxicological properties of compounds, including on-and off-target effects, dose responses, and the discrimination of closely related compounds.
# # #
Contacts:
About Asterand Asterand plc is a leading supplier of high quality human tissue and tissue-based services. Our comprehensive approach to human tissue and research services offers pharmaceutical, biotech and diagnostic companies the unique opportunity to have one company meet all of their human biomaterial needs along the continuum of drug discovery and development. Our mission is to accelerate target discovery and compound validation and enable pharmaceutical and biotechnology companies to take safer and more effective drugs into the market. For more information about Asterand or BioSeek, go to www.asterand.com.
About Ono Pharmaceutical Co., Ltd.
Ono Pharmaceutical Co., Ltd. is a R&D-oriented pharmaceutical company specialized in creating innovative medicines in specific areas and is headquartered in Osaka, Japan. For more information about Ono, visit the company's website at www.ono.co.jp.
This information is provided by RNS The company news service from the London Stock Exchange More |
||||||||||||||||||||||||||||||||
| 18-11-11 | RNS |
|||||||||||||||||||||||||||||||
|
RNS Number : 3321S Asterand PLC 18 November 2011 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF THAT JURISDICTION. This announcement is not an announcement of a firm intention to make an offer under Rule 2.7 of the City Code on Takeovers and Mergers (the "Takeover Code") and there can be no certainty that an offer will be made, nor as to the terms on which any offer will be made. 18 November 2011 Asterand Plc ("Asterand" or the "Company") Update on Formal Sale Process
On 24 October 2011, the Company announced the commencement of a formal sale process with the intention of targeting the second half of November for determining a potential offer for the Company. The deadline was predicated on the estimates at that time of the Company's short term cash flows and the need to deal with the creditors with whom the Company is currently in default. As announced in the Company's Interim Management Statement released this morning, the Board has reviewed the cash flow projections and, after discussions with the main secured creditors, the Board now believes that there will be sufficient cash to last the Company into the early part of 2012. The original deadline had provided only a short time frame for due diligence and, given the several credible approaches received by the Company since 24 October and revised cash position, the Board, has decided to extend the timeframe to allow potential offerors more time to carry out due diligence prior to considering whether to make an offer. The revised intended timeframe is as follows:
Shareholders should note that whilst the Board is working to secure a recommended offer by the middle of January 2012, there is no guarantee that an offer will be made, or even proposed, or as to the level of any proposal or offer that may be made. If a recommended offer is secured by the targeted date, the Board anticipates that an offer document would then be posted in the following 28 days. The Board is also pleased to announce that it has appointed Covington Associates LLC (www.covllc.com), a US based investment bank which specialises in the healthcare sector, to assist the Company and Daniel Stewart in negotiations with potential offerors. The Board reserves the right to alter any aspect of the sale process as outlined above or to terminate it at any time and in such cases will make an announcement as appropriate. As highlighted in today's Interim Management Statement by the Company, the improvement in trading is overshadowed by the issues with the Company's balance sheet and whilst the Board is encouraged by the interest that it has received following the announcement of the formal sale process, it continues to evaluate the potential for refinancing discussions in parallel with the formal sale process. The Board reserves the right to reject any approach or terminate discussions with any interested party or participant at any time. For further information, please contact:
A copy of this announcement will be available at www.asterand.co.uk. The content of the website referred to in this announcement is not incorporated into and does not form part of this announcement. Daniel Stewart & Company Plc ("Daniel Stewart") (which is authorised and regulated in the United Kingdom by the Financial Services Authority) is acting exclusively for the Company and for no one else in connection with any possible offer and will not be responsible to anyone other than the Company for providing the protections afforded to Daniel Stewart's clients nor for providing advice in relation to any possible offer or any other matters referred to in this announcement. This announcement is not intended to, and does not, constitute or form part of any offer, invitation or the solicitation of an offer to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of, any securities whether pursuant to this announcement or otherwise. The distribution of this announcement in jurisdictions outside the United Kingdom may be restricted by law and therefore persons into whose possession this announcement comes should inform themselves about, and observe, such restrictions. Any failure to comply with the restrictions may constitute a violation of the securities law of any such jurisdiction. Disclosure requirements of the Code Under Rule 8.3(a) of the Code, any person who is interested in 1% or more of any class of relevant securities of an offeree company or of any paper offeror (being any offeror other than an offeror in respect of which it has been announced that its offer is, or is likely to be, solely in cash) must make an Opening Position Disclosure following the commencement of the offer period and, if later, following the announcement in which any paper offeror is first identified. An Opening Position Disclosure must contain details of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any paper offeror(s). An Opening Position Disclosure by a person to whom Rule 8.3(a) applies must be made by no later than 3.30 pm (London time) on the 10th business day following the commencement of the offer period and, if appropriate, by no later than 3.30 pm (London time) on the 10th business day following the announcement in which any paper offeror is first identified. Relevant persons who deal in the relevant securities of the offeree company or of a paper offeror prior to the deadline for making an Opening Position Disclosure must instead make a Dealing Disclosure. Under Rule 8.3(b) of the Code, any person who is, or becomes, interested in 1% or more of any class of relevant securities of the offeree company or of any paper offeror must make a Dealing Disclosure if the person deals in any relevant securities of the offeree company or of any paper offeror. A Dealing Disclosure must contain details of the dealing concerned and of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any paper offeror, save to the extent that these details have previously been disclosed under Rule 8. A Dealing Disclosure by a person to whom Rule 8.3(b) applies must be made by no later than 3.30 pm (London time) on the business day following the date of the relevant dealing. If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire or control an interest in relevant securities of an offeree company or a paper offeror, they will be deemed to be a single person for the purpose of Rule 8.3. Opening Position Disclosures must also be made by the offeree company and by any offeror and Dealing Disclosures must also be made by the offeree company, by any offeror and by any persons acting in concert with any of them (see Rules 8.1, 8.2 and 8.4). Details of the offeree and offeror companies in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure Table on the Takeover Panel's website at www.thetakeoverpanel.org.uk, including details of the number of relevant securities in issue, when the offer period commenced and when any offeror was first identified. If you are in any doubt as to whether you are required to make an Opening Position Disclosure or a Dealing Disclosure, you should contact the Panel's Market Surveillance Unit on +44 (0)20 7638 0129. This information is provided by RNS The company news service from the London Stock Exchange More |
||||||||||||||||||||||||||||||||
| Result Pages: 1 | ||||
| Date/Time | Subject | Author | ||
|---|---|---|---|---|
| Thu 07:45 | ||||
|
|
||||
|
|
||||
|
US Environmental Protection Agency expands ToxCast collaboration with BioSeek
Detroit Thursday, February 02, 2012, 13:00 Hrs [IST] http://bit.ly/xlWGAR |
||||
| 31-01-12 | ||||
|
|
||||
|
|
||||
|
Asterand Subsidiary BioSeek and US EPA Expand ToxCast(TM) Collaboration
BioSeek's BioMAP(R) Systems Platform Used to Predict Toxicity of Environmental and Other Compounds on Human Health Jan. 31, 2012, 11:00 a.m. EST http://bit.ly/wVB2Tx |
||||
| 30-01-12 | ||||
|
|
||||
|
|
||||
|
Asterand up on subsidiarys US deal
January 30, 2012 10:22 pm By David Keohane http://on.ft.com/xwBFPJ |
||||
| 30-01-12 | ||||
|
|
||||
|
|
||||
|
Asterand's BioSeek gets additional funding from US EPA
30 January 2012 | 14:42pm http://bit.ly/A7QInO |
||||
|
|
||||
They have not been approved or issued by Interactive Investor Trading Limited.
Editor's Pick:
Glenstrata's just a silly word. Stick to big dividendsEditor's Pick:
Bulls should head for ChinaEditor's Pick:
Stock to Watch: Imperial TobaccoEditor's Pick:
George Godber’s AIM stock picks

